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Abstract
Background Fostamatinib (R788) is a spleen tyrosine
kinase (SYK) inhibitor. The active metabolite of fostama-
tinib, R406, is primarily metabolized by CYP3A4.
Objectives The aim of this study was to characterize hep-
atic microsomal metabolism of R406 and confirm the role of
CYP3A4 in R406 metabolism, determining whether co-ad-
ministration of CYP3A4 inhibitors (ketoconazole, verapamil)
or inducers (rifampicin) affects R406 pharmacokinetics.
Methods R406 stability was determined using human
hepatic microsomes. The CYP450 isoforms responsible for
R406 metabolism in humans were identified using
expressed CYP450 isoforms and specific chemical inhibi-
tors. The ketoconazole interaction study (double-blind,
randomized, placebo-controlled, two-period crossover)
involved fostamatinib administration (single 80-mg dose),
alone and with ketoconazole (200 mg twice daily). The
verapamil and rifampicin interaction studies (open-label,
two-period, fixed-sequence) involved fostamatinib admin-
istration (single 150-mg dose), alone and with immediate-
release verapamil (80 mg three times daily) or rifampicin
(600 mg once daily). Standard pharmacokinetic parameters
were calculated in all studies.
Results/Discussion Hepatic microsomes showed time-de-
pendent loss of R406 and formation of para-O-demethylated
R406. Microsomal metabolism of R406 was markedly inhib-
ited by CYP3A4 inhibitors and, in the expressed CYP450
studies, the rate of R406 disappearance was greatest with
CYP3A4. In the clinical studies, co-administration of keto-
conazole caused a 2-fold (CI 1.77–2.30) increase in R406
exposure. Verapamil increased R406 exposure (39 % increase,
CI 8–80), whereas rifampicin co-administration decreased
exposure by 75 % (CI 68–81). Fostamatinibwaswell tolerated.
Conclusion The oxidative metabolism of R406 is pre-
dominantly catalyzed by CYP3A4. In clinical studies,
exposure to R406 is affected by concomitant administra-
tion of CYP3A4 inducers/inhibitors. These findings should
be taken into account when considering co-prescription of
fostamatinib with such agents.
Key Points
The oxidative metabolism of R406 (the active
metabolite of fostamatinib/R788) is predominantly
catalyzed by CYP3A4.
Exposure to R406 is affected by concomitant
administration of CYP3A4 inducers/inhibitors; co-
administration of ketoconazole caused a 2-fold
increase in R406 exposure, verapamil increased
R406 exposure by 39 %, and rifampicin co-
administration decreased exposure by 75 %.
The findings from these studies should be taken into
account when considering co-prescription of
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1 Introduction
Fostamatinib (previously known as R788) is an orally
dosed spleen tyrosine kinase (SYK) inhibitor [1] that has
completed phase III clinical trials as a therapy for the
treatment of rheumatoid arthritis (RA) in patients who have
shown inadequate response to traditional disease-modify-
ing anti-rheumatic drugs or parenteral tumor necrosis fac-
tor-a antagonists [2–4].
Fostamatinib is a prodrug that is metabolized to its active
metabolite, R406, by intestinal alkaline phosphatase [5].
R406 undergoes both direct glucuronidation and CYP3A4-
mediated para-O-demethylation to form themajormetabolite,
R529 [5]. R788 and R529 are much less active against syk
than R406. Subsequent O-demethylations and dehydroxyla-
tion of R529 by gut bacteria lead to formation of the major
excretory metabolite of R406, 3,5-benzene diol [5]. Activity
of CYP3A4 is therefore integral to the metabolism of fosta-
matinib. Drugs can alter the activity of CYP3A4, acting either
as inhibitors (e.g., ketoconazole [potent inhibitor], verapamil
[moderate inhibitor]) or inducers (e.g. rifampicin [potent
inducer]). These drugs may therefore alter the pharmacoki-
netics of any co-administered drug that is metabolized by this
enzyme. Given the increased risk of co-morbidities for
patients with RA, polypharmacy is commonly required [6–9].
The variety of concomitant medications may often include
inhibitors or inducers of CYP3A4.
We report here the results of a series of in vitro studies
designed to characterize the hepatic microsomal metabo-
lism of R406 and to confirm the role of CYP3A4 in the
metabolism of fostamatinib. We also performed clinical
studies in which the CYP3A4 inhibitors ketoconazole (a
potent inhibitor) and verapamil (a moderate inhibitor) and
the CYP3A4 inducer rifampicin were co-administered with
fostamatinib to healthy subjects to assess the potential for
pharmacokinetic interactions. This was also intended to
determine if any changes in the fostamatinib dose regimen
would be needed if fostamatinib was co-administered with
any of these three compounds in clinical practice. Keto-
conazole, verapamil, and rifampicin are regarded as pro-
totypical CYP3A4 modulators and are typically used in
drug interaction studies that aim to determine the effect of
CYP3A4 modulation on drug pharmacokinetics [10].
2 Methods
2.1 In Vitro Experiments
2.1.1 Materials
Human hepatic microsomes were obtained from Xenotech
(Lenexa, KS, USA) and expressed CYP1A2, CYP2C9*1
?OR, CYP2C19 ?OR, CYP2E1?OR? cytochrome b5,
CYP2D6*1?OR, and CYP3A4 ?OR were purchased from
Gentest (Woburn, MA, USA). The designation ‘?OR’
signifies that the preparation contained supplemental,
cDNA-expressed cytochrome P450 reductase. Ketocona-
zole, dextromethorphan, dextrorphan, diclofenac, phena-
cetin, acetamidophenol, testosterone, 6-b-hydroxy-
testosterone, midazolam, quinidine, sulfaphenazole, and
nicotinamide adenine dinucleotide phosphate (NADPH)
were acquired from Sigma Chemical Co (St Louis, MO,
USA). S-(?)-mephenytoin, 40-hydroxy-mephenytoin, 10-
hydroxy-midazolam, and 40-hydroxy-diclofenac were
obtained from Ultrafine Chemicals (Manchester, UK). 3-N-
benzylnirvanol was purchased from Gentest. All other
chemicals were the highest grades available.
2.1.2 Microsomal Stability and Metabolite Profile of R406
The stability of R406 was determined using human hepatic
microsomes. Reactions were performed at 37 C at a final
volume of 502 lL (445 lL 0.1 M phosphate buffer [pH
7.4], 5 lL microsomes [0.1 mg protein], 2 lL R406 in
dimethyl sulfoxide [DMSO; final concentration, 1 lM],
and 50 lL NADPH [final concentration, 1 mM]). Meta-
bolic reactions were initiated by addition of the NADPH
solution and stopped at 0, 15, 30, and 50 min. R406 con-
centrations were determined using high-performance liquid
chromatography, followed by mass spectrometry in the
multiple reaction monitoring (MRM) mode.
Metabolites were determined following incubation of
10 lM R406 with human hepatic microsomes (1 mg pro-
tein/mL). Reactions were terminated after 15 min. The
precipitate was removed by centrifugation and 10 lL of the
supernatant was analyzed by liquid chromatography/mass
spectrometry with ultraviolet (254 nm) detection.
2.1.3 Metabolic Phenotyping
Studies using expressed CYP450 isoforms and specific
chemical inhibitors were performed to identify the CYP450
isoforms responsible for metabolism of R406 in humans.
The chemical CYP450 inhibitors were ketoconazole
(1 lM, CYP3A4), troleandomycin (100 lM, CYP3A4),
furafylline (10 lM, CYP1A2), quinidine (10 lM,
CYP2D6), sulfaphenazole (10 lM, CYP2C9), and 3-N-
benzylnirvanol (5 lM, CYP2C19). Incubation conditions
for these microsomal metabolism studies were similar to
those described above. All inhibitors were added in 1 lL of
methanol. Because of the time-dependent inactivation of
CYP450 produced by furafylline and troleandomycin,
these inhibitors were pre-incubated with the microsomes
and NADPH for 15 min prior to addition of R406. Reac-
tions were terminated at 0, 15, 30, and 50 min and R406
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concentrations were determined by mass spectrometry in
MRM mode. First-order rate constants for R406 disap-
pearance were calculated by linear regression using
Microsoft Excel (Microsoft Corporation, Redmond, WA,
USA) and comparisons were made using these values.
For the expressed CYP450 studies, 20 pmol of
CYP3A4, CYP1A2, CYP2D6*1, CYP2C19, CYP2C9*1,
or CYP2E1 were added in place of the hepatic microsomes.
All phenotyping reactions were terminated at 0, 15, 30, and
50 min and analyzed by mass spectrometry in MRM mode.
Rate calculations were based on the amount of R406 lost at
the 15-min time point.
2.2 Clinical Studies
2.2.1 Subject Populations
Healthy male subjects aged 18–45 years with a body mass
index (BMI) between 19 and 28 kg/m2 were eligible for
enrollment in the ketoconazole study (C-935788-001). In
the rifampicin (NCT01336218) and verapamil
(NCT01197781) studies, eligibility criteria were similar:
healthy male or female subjects aged 18–55 years with a
minimum weight of 50 kg and BMI between 18 and 35 kg/
m2.
Exclusion criteria for the three studies included a history
or the presence of any clinically relevant condition,
including gastrointestinal, renal, or hepatic disease; recent
administration of drugs with enzyme-inducing properties
(e.g., St John’s Wort); a history of excessive alcohol con-
sumption; use of any investigational drug and/or partici-
pation in any clinical trial within 4 months (ketoconazole
study) or 1 month (verapamil and rifampicin studies) of
first dosing; and previous administration of fostamatinib
(R788). In the verapamil and rifampicin studies, subjects
were also excluded if they had an absolute neutrophil count
of\2500/mm3 at screening.
2.2.2 Clinical Study Designs
The designs of the three clinical studies, each of which was
conducted at a single center, are summarized in Table 1.
The ketoconazole interaction study was a double-blind,
randomized, placebo-controlled, two-period crossover trial
in which eight male subjects received a single dose of
fostamatinib (80 mg) on the second of 4 days of treatment
with either ketoconazole (200 mg twice daily) or placebo.
In this study, fostamatinib was administered as a suspen-
sion in orange juice. The verapamil and rifampicin inter-
action studies were both open-label, two-period, fixed-
sequence trials that enrolled 15 male or female subjects. In
period 1 of each study, the only drug administered was a
single 150-mg dose of fostamatinib (administered on day 1
of period 1). In period 2 of each study, a single 150-mg
dose of fostamatinib was administered in conjunction with
immediate-release verapamil (80 mg three times daily
from day 1 to day 4 of period 2, with fostamatinib
administered on day 2) or rifampicin (600 mg once daily
from day 1 to day 8 of period 2, with fostamatinib
administered on day 6). In these studies, fostamatinib was
administered in tablet form. Suitable washout periods were
employed between sequential doses of fostamatinib in all
studies (Fig. 1). In phase III trials, fostamatinib doses of
150 mg once daily and 100 mg twice daily were used and
therefore a dose of 150 mg was chosen to assess drug
interactions in the current studies with rifampicin and
verapamil which were run relatively late in development. A
dose of fostamatinib 80 mg was used in the ketoconazole
study as this study was run earlier in development before a
phase II/III dose was set.
2.2.3 Study Endpoints
The objective of the ketoconazole study was to assess the
effects of multiple oral doses of ketoconazole on the single-
dose pharmacokinetics of fostamatinib (R788) and its
metabolite, R406. The primary aims of the verapamil and
rifampicin interaction studies were to assess the pharma-
cokinetics of R406 in healthy subjects when fostamatinib
was administered alone and in combination with verapamil
or rifampicin. All three studies also examined the safety
and tolerability of fostamatinib when given in combination
with ketoconazole, verapamil, or rifampicin.
2.2.4 Pharmacokinetic Assessments
Whole blood was collected via venous catheter into ethy-
lene diamine tetra acetate. Samples were chilled prior to
centrifugation (speed, 1500g; temperature, 4 C; duration,
10 min; performed within 30 min of sampling) and plasma
was collected and stored at -80 C within 30 min of
centrifugation. In the ketoconazole interaction study, blood
samples were collected for pharmacokinetic analysis prior
to, and between 0.25 and 120 h after, fostamatinib
administration (Table 1). A pre-fostamatinib-dose blood
sample was also collected in the verapamil and rifampicin
interaction studies and the period over which blood sam-
ples were collected was extended from 0.5 to 96 h post-
dose in these studies (Table 1).
Validated liquid chromatography tandem mass spec-
trometry methods were used to determine the plasma levels
of R406 in all three clinical studies, and of R788 in the
ketoconazole interaction study. In the verapamil and
rifampicin interaction studies, the lower limit of quantita-
tion (LLOQ) for R406 was 2.50 ng/mL. In the
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ketoconazole interaction study, the LLOQs for R788 and
R406 were 0.5 and 0.25 ng/mL, respectively.
For the verapamil study, the precision (% CV) and
accuracy (% bias) for the quality control samples at three
concentrations were B3.5 % and were within -7.5 to
0.9 %. For the rifampicin study, the precision and accuracy
were B6.9 % and were within -6.5 to -4.0 %,
respectively.
For the ketoconazole study, the precision and accuracy
were B13.7 % and were within -10.9 to –1.0 %,
respectively.
2.2.5 Pharmacokinetic Analysis
Pharmacokinetic parameters were derived using standard
non-compartmental methods. In the ketoconazole interac-
tion study, all samples were assayed for R406 levels but,
because previous work had shown that plasma R788 con-
centrations are negligible after oral fostamatinib adminis-
tration, only selected samples were assayed for R788. In all
studies, the maximum plasma concentration (Cmax), time to
Cmax (tmax), terminal half-life (t), and area under the curve
from zero to infinity (AUC0–?) for R406 were determined.
Table 1 Schedule of drug
administration and
pharmacokinetic assessments in
the three clinical studies
Study Day
1 2 3 4 5 6 7 8 9 10
Ketoconazole interaction study
Periods 1 and 2
Drug administration
Ketoconazole (200 mg twice daily) or placeboa ? ? ? ?
Fostamatinib (80 mg)b ?




Fostamatinib (150 mg)d ?
Pharmacokinetic assessmentse ? ? ? ? ?
Period 2
Drug administration
IR verapamil (80 mg three times daily) ? ? ? ?
Fostamatinib (150 mg)d ?




Fostamatinib (150 mg)d ?
Pharmacokinetic assessmentse ? ? ? ? ?
Period 2
Drug administration
Rifampicin (600 mg once daily) ? ? ? ? ? ? ? ?
Fostamatinib (150 mg)d ?
Pharmacokinetic assessmentse ? ? ? ? ?
IR immediate release
a First dose administered on evening of day 1, last dose on evening of day 4
b Single dose administered as powder in orange juice 120 min after completion of breakfast and 135 min
after administration of ketoconazole/placebo
c Blood samples collected prior to and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 56, 72, 96, and 120 h
after fostamatinib administration
d Single dose (3 9 50-mg tablets) administered with water; administered at the same time as verapamil/
rifampicin in period 2; all subjects required to fast from 10 h prior to until 4 h after administration of
fostamatinib
e Blood samples collected prior to and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 h after
fostamatinib administration
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In the verapamil and rifampicin interaction studies, the
pharmacokinetics of R406, but not R788, were determined.
2.2.6 Safety Assessments
In all three studies, safety and tolerability assessments
included the incidence and severity of adverse events
(AEs), vital signs, physical examination, clinical laboratory
data, and electrocardiograms. AEs were tabulated and
summarized according to the Medical Dictionary for
Regulatory Activities (MedDRA).
2.2.7 Statistical Analysis
In the ketoconazole interaction study, the sample size of
eight (four subjects randomized to each sequence in a two-
way crossover design) was chosen to allow detection of
clinically significant increases in exposure (95 % power to
detect a 50 % increase in exposure [one-sided test at 5 %
significance level], assuming a within-subject coefficient of
variation [CV] of 25 %;[99 % power to detect doubling
of exposure). The verapamil and rifampicin interaction
studies were not powered to allow pursuit of a claim of no
effect of verapamil/rifampicin on exposure to R406 (pos-
sible if the treatment ratio 90 % confidence intervals [CIs]
were between 80 % and 125 %). Therefore, the results of
the verapamil and rifampicin interaction studies were
interpreted based on the size of the treatment ratio and
associated 90 % CI. Assuming inter-subject CVs of 27 %
for AUC and 29 % for Cmax (data based on a previous
unpublished study), it was estimated that 12 subjects would
provide 80 % power to detect treatment ratios of C134 %
(verapamil) and B75 % (rifampicin) in these two param-
eters (two-sided test at 5 % significance level).
In the ketoconazole interaction study, all subjects who
received at least one dose of fostamatinib were included in
the pharmacokinetic analysis and all subjects who received
treatment were included in the safety analysis. Pharma-
cokinetic data were summarized using descriptive statistics
including n, mean, SD, median, minimum (min), and
maximum (max) values. Additional analyses (calculation
of treatment ratios and CIs) were performed to investigate
the effect of ketoconazole co-administration on the AUC
and Cmax of R406.
In the verapamil and rifampicin interaction studies, the
pharmacokinetic analysis sets included only subjects who
had received at least one dose of fostamatinib and who had
at least one post-dose pharmacokinetic measurement
without important protocol deviations or violations that
might substantially affect pharmacokinetics (e.g., vomiting
after drug administration). The safety sets in these studies
comprised all subjects who had received at least one dose
of fostamatinib and for whom at least one post-dose safety
assessment was available. Quantitative continuous vari-
ables were summarized using descriptive statistics. Addi-
tionally, for all pharmacokinetic parameters except tmax,
geometric means and geometric CVs were reported and
categorical variables were summarized in frequency tables.
The effects of verapamil and rifampicin on R406 were
determined by analyzing Cmax and AUC data from subjects
with valid data from both periods 1 and 2 using an analysis
of variance model with fixed effects for treatment and
subject. Least-squares geometric means, two-sided 95 %
CIs, and ratios of geometric means, together with two-

























































































Fig. 1 Determination of the CYP450 isoforms involved in R406
metabolism by using specific chemical inhibitors and expressed
enzymes
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verapamil/rifampicin) and reference treatment (fostama-
tinib alone) were estimated.
In the ketoconazole interaction study, pharmacokinetic
parameters were analyzed using WinNonlin Professional
(Pharsight Corporation, Cary, NC, USA; Version 4.1) and
Microsoft Excel (Microsoft Corporation, Redmond, CA,
USA). In the verapamil and rifampicin interaction studies,
all analyses were conducted using SAS v9.2 (SAS Insti-
tute Inc, Cary, NC, USA), WinNonlin Professional v5.2
(Pharsight Corp, Mountain View, CA, USA), and Sig-
maPlot v9.01 (verapamil)/v9.0 (rifampicin) (Systat Soft-
ware Inc, San Jose, CA, USA).
3 Results
3.1 In Vitro Experiments
3.1.1 Microsomal Stability and Metabolite Profile of R406
Hepatic microsomes showed time-dependent loss of R406
(microsomal half-life, 24.4 min). Liquid chromatogra-
phy/mass spectrometry showed that un-metabolized R406
eluted at 40 min and the major metabolite (para-O-
demethylated R406, R529) eluted at 34 min. Other
unidentified metabolites were also observed.
3.1.2 Metabolic Phenotyping
The studies involving CYP450 inhibitors and expressed
CYP450 isoforms demonstrated that CYP3A4 plays a
major role in the oxidative metabolism of R406. Micro-
somal metabolism of R406 was markedly inhibited by
ketoconazole and troleandomycin (CYP3A4 inhibitors)
whereas all other inhibitors had a minimal effect on R406
disappearance (Fig. 1a). Moreover, in the expressed
CYP450 studies, the rate of disappearance of R406 (pmol
R406 metabolized/pmol CYP450/min) was greatest with
CYP3A4 (Fig. 1b). In these studies, only expressed
CYP3A4 and CYP2C9*1 were found to metabolize R406,
but the rate of R406 disappearance was 5.6-fold greater
with CYP3A4 than with CYP2C9*1.
3.2 Clinical Study
3.2.1 Subject Demographics
All subjects who enrolled in the ketoconazole and rifam-
picin interaction studies (N = 8 and N = 15, respectively)
completed the study per protocol. Three of the 15 subjects
who enrolled in the verapamil interaction study withdrew
and 12 completed. No withdrawals from the study were
because of safety reasons. Baseline characteristics of all
subjects are shown in Table 2. All 38 subjects were male.
3.3 Pharmacokinetics
3.3.1 Ketoconazole Interaction Study
No pharmacokinetic parameters are reported for the parent
compound because plasma levels of R788 were negligible,
both when fostamatinib was administered with ketocona-
zole-placebo and when it was administered in conjunction
with ketoconazole. The highest concentration of R788
obtained in any subject was\7 ng/mL, and no quantifiable
R788 (i.e., above 0.5 ng/mL) was obtained beyond 2 h










Male, n (%) 8 (100) 15 (100) 15 (100)
Female, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Age, years; mean (SD) 23 (3) 32 (12) 33 (10)
Race
White, n (%) 8 (100.0) 7 (46.7) 8 (53.3)
Black/African American, n (%) 0 (0.0) 6 (40.0) 6 (40.0)
American Indian/Alaskan Native, n (%) 0 (0.0) 2 (13.3) 0 (0.0)
Asian, n (%) 0 (0.0) 0 (0.0) 1 (6.7)
Height, m; mean (SD) 1.82 (0.05) 1.77 (0.07) 1.76 (0.04)
Weight, kg; mean (SD) 78.0 (6.9) 86.6 (15.3) 80.3 (10.4)
BMI, kg/m2; mean (SD) 23.5 (1.6) 27.5 (3.4) 25.9 (3.8)
BMI body mass index, SD standard deviation
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post-dose in any subject. Co-administration of ketocona-
zole (200 mg twice daily) increased plasma R406 exposure
after administration of 80 mg fostamatinib (Figs. 2a, 3a).
Average increases in Cmax and AUC0–? after co-adminis-
tration of ketoconazole were 37 and 102 %, respectively,
and the 90 % CIs for the estimate of the ratio of least
squares geometric means of Cmax and AUC0–? with and
without ketoconazole exceeded 125 % (Cmax, 123–153 %;
AUC0–?, 177–230 %) (Table 3). Ketoconazole co-ad-
ministration increased the tmax of R406 from 1.38 h (fos-
tamatinib alone) to 1.69 h (fostamatinib plus ketoconazole)
and the average t increased from 14.2 to 18.4 h in asso-
ciation with ketoconazole co-administration.
3.3.2 Verapamil Interaction Study
Higher plasma levels of R406 were observed after co-ad-
ministration of fostamatinib (150 mg) and verapamil
(80 mg three times daily) than after administration of fos-
tamatinib alone (Figs. 2b, 3b). R406 AUC was higher after
verapamil co-administration in 10 of the 13 subjects, with
an average increase in the co-administration period of 39 %
(90 % CI for ratio, 108–180) (Table 3). There was no
consistent effect of verapamil co-administration on R406
Cmax, least square geometric mean ratios for individual
subjects ranging from 34 to 275 % with an average of
106 % and a 90 % CI of 78–144. Similarly, there was no
consistent effect of verapamil on R406 tmax. There did not
appear to be any specific relationship between changes in
Cmax and tmax (e.g., higher Cmax was not always associated
with later tmax). The median tmax was similar between fos-
tamatinib alone (1.48 h) and fostamatinib plus verapamil
(1.50 h). Average t increased by 41 % from 13.5 to 19.1 h
in association with verapamil co-administration (Table 3).
3.3.3 Rifampicin Interaction Study
Plasma levels of R406 were lower after co-administration
of fostamatinib (150 mg) and rifampicin (600 mg once
daily) than after administration of fostamatinib alone
(Figs. 2c, 3c). The geometric least squares mean ratios for
AUC and Cmax were 25 and 41 %, respectively, with 90 %
CIs that were below 80 % for both parameters (Cmax,
30–56 %; AUC, 19–32 %) (Table 3). There was no con-
sistent effect of rifampicin co-administration on tmax, but
median tmax values were shorter after rifampicin/fostama-
tinib co-administration (1 h) than after fostamatinib
monotherapy (2 h). The geometric mean R406 t for R406
decreased from 15.0 to 10.8 h in association with rifam-
picin co-administration (Table 3).
3.4 Safety Assessments
Fostamatinib was well tolerated in all three clinical studies,
both when administered alone and in combination with a
CYP3A4 inducer/inhibitor. There were no deaths, serious
AEs, withdrawals due to AEs or severe AEs in any of the
studies, nor were there any clinically relevant trends in
laboratory test results, vital signs, physical findings, or
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Fig. 2 Mean R406 concentration–time profiles in the three clinical
studies. a Ketoconazole interaction study. b Verapamil interaction
study. c Rifampicin interaction study
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3.4.1 Ketoconazole Interaction Study
A total of eight AEs, six of which were treatment-emer-
gent, were reported. The two AEs that occurred prior to
administration of fostamatinib comprised mild low back
pain (after administration of ketoconazole) and mild
headache (after placebo). The treatment-emergent AEs
(headache, three events; low back pain, three events) were
reported by five of the eight subjects, all of whom were























































































































































Fig. 3 Individual and geometric mean R406 Cmax and AUC values in both treatment periods in the three clinical studies. a Ketoconazole
interaction study. b Verapamil interaction study. c Rifampicin interaction study
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ketoconazole alone. No treatment-emergent AEs were
reported by subjects receiving fostamatinib and ketocona-
zole. All treatment-emergent AEs were considered mild in
intensity.
3.4.2 Verapamil Interaction Study
A total of three AEs in three patients (one mild, two
moderate in severity) were reported. These occurred in all
treatment arms (i.e., one AE per treatment arm reported).
These comprised bacterial dermatitis, superficial phlebitis,
and headache. None of these AEs were considered by the
investigators to be related to administration of
fostamatinib.
3.4.3 Rifampicin Interaction Study
A total of four AEs were recorded in this study, one in each
of four subjects (one occurred in the rifampicin-only arm,
two in the rifampicin/fostamatinib arm, and one in the
fostamatinib-only arm). All were mild in intensity. One AE
of pollakiuria (frequent urination), which began during
rifampicin monotherapy, was regarded by the investigator
as being causally related to rifampicin administration. The
remaining AEs, all of which were considered unrelated to
fostamatinib administration, comprised pain in an extrem-
ity (two subjects) and headache (one subject).
4 Discussion
Treatment of patients with RA is often complicated by the
presence of comorbidities [6–8]. As a consequence,
patients with RA often require polypharmacy. Drug–drug
interactions (DDIs) are therefore a concern, and should be
assessed. As CYP3A4 is involved in the metabolism of a
substantial percentage (30–50 %) of drugs [11] (including
R406, the active metabolite of fostamatinib), it is important
to establish whether concomitant administration of
CYP3A4 inducers or inhibitors affects the pharmacoki-
netics of fostamatinib or R406.
The in vitro work reported in this paper has demon-
strated that R406 can be metabolized by an NADPH-de-
pendent process, that CYP3A4 plays a major role in the
oxidative metabolism of R406, and that the primary route
of hepatic microsomal metabolism of R406 is para-O-
demethylation. These findings concur with results obtained
by Sweeny et al., who demonstrated that R406 undergoes
both direct glucuronidation and CYP3A4-mediated para-O-
demethylation [5]. The product of O-demethylation—the
major metabolite of R406—is designated R529 [5]. R529 is
further metabolized to a 3,5-benzene diol metabolite,
which is the major fecal metabolite of fostamatinib in
humans [5]. It is therefore evident that CYP3A4 plays an
important role in the metabolism of R406. The only other
isoform that was found to metabolize R406 in the current
study was CYP2C9. However, hepatic microsomal levels
of CYP3A4 are on average 5-fold higher than those of
CYP2C9 (101.5 pmol/mg vs 18 pmol/mg) [12, 13]. It can
therefore be estimated that CYP3A4 accounts for[96 % of
total CYP450 oxidative metabolism of R406 in human
liver.
This in vitro work is supported by the results of the three
clinical studies that explored the clinical relevance of
CYP3A4 activity in fostamatinib-treated subjects, using
agents that are typically used to determine the effects of
CYP3A4 modulation on drug pharmacokinetics [10]. The
studies reported herein indicate that ketoconazole, a strong
CYP3A4 inhibitor, is associated with a 2-fold increase in
exposure to R406 after administration of fostamatinib. It is
likely that this ketoconazole-induced increase in R406
exposure is mediated via inhibition of CYP3A4 metabo-
lism. However, based on the definitions in the current US
Food and Drug Administration (FDA) guidance [14], R406
would not be considered a ‘‘sensitive substrate’’ of CYP3A.
This designation is reserved for substrates that show C5-
fold increase in exposure in response to co-administration
with strong CYP3A inhibitors [14]. Since completion of
this study, the FDA has recommended that clarithromycin
or itraconazole be used as an alternative strong CYP3A in
drug interaction studies, rather than ketoconazole, to
reduce the risk of liver injury [15].
The effect on R406 pharmacokinetics by verapamil, a
moderate CYP3A4 inhibitor, was less marked than that of
ketoconazole. However, there were still increases in AUC
and t of approximately 50 %, although no consistent
effect on Cmax and tmax was observed with verapamil co-
administration. Co-administration of the CYP3A4 inducer,
rifampicin, was associated with reductions of approxi-
mately 75 % in R406 AUC and 60 % in R406 Cmax. This
reduction in R406 exposure was associated with a decrease
in t and a shortening of median tmax. Previous work has
shown that rifampicin acts as an inducer of uridine
diphosphate glucuronosyltransferase 1A9-mediated glu-
curonidation [16], and it is therefore possible that
glucuronidation of R406 was also increased by co-admin-
istration of rifampicin. It is possible that ketoconazole,
verapamil and rifampicin altered expression or activity of
protein transporters including P-glycoprotein that may
have contributed to the interactions observed.
These studies have demonstrated that pharmacokinetic
interactions occur when fostamatinib is administered in
combination with ketoconazole, verapamil, and rifampicin.
It is possible that the decrease in fostamatinib exposure
associated with rifampicin co-administration may lead to a
decrease in efficacy. This should be taken into account
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when considering co-prescription of fostamatinib with such
agents. It is a recognized limitation of the clinical studies
performed that they are single dose studies that provide
indicative pharmacokinetic DDI potential but may not fully
characterize the DDI risk or safety in the patient popula-
tion. As ketoconazole has been withdrawn in some terri-
tories, it may not be considered as an ideal potent CYP3A4
inhibitor probe but we believe the data do provide useful
information to assess DDI risk through this mechanism.
No new safety concerns were documented during these
three clinical studies. It is acknowledged, however, that
these studies all involved administration of a single dose of
fostamatinib to a small number of subjects—a design that
is typical of DDI studies, but which is unable to explore the
effects of long-term doubling of R406 exposure in humans.
It is unlikely that the difference among studies in fos-
tamatinib formulation (ketoconazole study: suspension in
orange juice; verapamil and rifampicin studies: tablets)
affected the bioavailability of fostamatinib. Moreover, as
no direct comparisons were made among the three studies,
any difference in bioavailability would not affect the
conclusions of each individual study.
5 Conclusions
The in vitro work presented herein has confirmed that the
primary route of hepatic microsomal metabolism for R406
is O-demethylation and that oxidative metabolism of R406
is predominantly catalyzed by CYP3A4. The studies pre-
sented in this paper demonstrate that metabolism of, and
exposure to, R406 (the active metabolite of fostamatinib) is
affected by concomitant administration of the stated
CYP3A4 inhibitors and inducers. Ketoconazole and vera-
pamil increased exposure to R406 after administration of
fostamatinib, probably via inhibition of CYP3A4-mediated
metabolism. In contrast, R406 exposure was decreased
after co-administration of the CYP3A4 inducer, rifampicin.
It is likely that this was caused by induction of CYP3A4-
mediated metabolism. Overall, fostamatinib was well tol-
erated when administered alone or in combination with
CYP3A4 inhibitors and inducers. These findings should be
taken into account when considering co-prescription of
fostamatinib with such agents.
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